The first FDA approved immunotherapy for the treatment of metastatic castration-resistant prostate cancer (mCRPC)
PROVENGE Treatment
Targeted immune response: PROVENGE starts with your patient’s own immune system and activates his antigen-presenting cells (APCs) to help the immune system target and attack prostate cancer cells.1,2
See the Science behind PROVENGE
First Cellular Immunotherapy
PROVENGE is the first FDA-approved immunotherapy using the patient’s own immune system to fight advanced prostate cancer. Clinical studies have shown that PROVENGE extends life for certain men with mCRPC.3
The Importance of Diagnosing mCRPC Early
Early identification of men with mCRPC is important for optimal outcomes and prolonged survival for patients. Almost 25% of men assumed to have non-metastatic CRPC were found to have metastatic disease when screened via imaging.4
PROVENGE is the only immunotherapy proven to extend life for mCRPC patients.
Resources for Clinicians
Use the following resources to help educate your patients about their treatment option with PROVENGE.
References
PROVENGE® (sipuleucel-T) is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate cancer.
Acute Infusion Reactions: Acute infusion reactions (reported within 1 day of infusion) may occur and include nausea, vomiting, fatigue, fever, rigor or chills, respiratory events (dyspnea, hypoxia, and bronchospasm), syncope, hypotension, hypertension, and tachycardia.
Thromboembolic Events: Thromboembolic events, including deep venous thrombosis and pulmonary embolism, can occur following infusion of PROVENGE. The clinical significance and causal relationship are uncertain. Most patients had multiple risk factors for these events. PROVENGE should be used with caution in patients with risk factors for thromboembolic events.
Vascular Disorders: Cerebrovascular events (hemorrhagic/ischemic strokes and transient ischemic attacks) and cardiovascular disorders (myocardial infarctions) have been reported following infusion of PROVENGE. The clinical significance and causal relationship are uncertain. Most patients had multiple risk factors for these events.
Handling Precautions: PROVENGE is not tested for transmissible infectious diseases.
Concomitant Chemotherapy or Immunosuppressive Therapy: Chemotherapy or immunosuppressive agents (such as systemic corticosteroids) given concurrently with the leukapheresis procedure or PROVENGE has not been studied. Concurrent use of immune-suppressive agents may alter the efficacy and/or safety of PROVENGE.
Adverse Reactions: The most common adverse reactions reported in clinical trials (≥ 15% of patients receiving PROVENGE) were chills, fatigue, fever, back pain, nausea, joint ache, and headache.